Online inquiry

IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3698MR)

This product GTTS-WQ3698MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3698MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12659MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ3218MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ7805MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ7240MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ5548MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ1527MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ3428MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ14246MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW